The in vitro activity of teicoplanin was compared with that of vancomycin against fecal isolates of Clostridium difficile. All strains were susceptible to both antibiotics, but teicoplanin was fourfold more active than vancomycin. Cholestyramine was found to bind teicoplanin almost completely, reducing its activity to nondetectable levels.
Vancomycin is considered the antibiotic of choice for the treatment of Clostridium difficile-induced pseudomembranous colitis (PMC) (6) . If orally administered, vancomycin reaches in feces a concentration largely exceeding the MIC for this microorganism (9) . Also, anion-exchange resins such as cholestyramine have proved useful in the treatment of PMC, due to direct inactivation of C. difficile toxin (8) . These different modalities of action suggest the possibility of a combined therapy; however, the binding of vancomycin by anion-exchange resins and the following decrease in its antibacterial activity raises some concern (3, 8) . Teicoplanin (teichomycin A2) is a new glycopeptide antibiotic closely associated with the group vancomycin-ristocetin (1), which has shown remarkable in vitro activity against gram-positive aerobes, such as staphylococci and enterococci (10) , and also against gram-positive anaerobes, including strains of C. difficile (4, 11) . The purpose of our study was (i) to compare the activity of teicoplanin and vancomycin against a large number of C. difficile strains recently isolated from patients with PMC or antibiotic-associated diarrhea and (ii) to examine the interaction between cholestyramine and teicoplanin and to evaluate whether a combined therapy would be compatible.
Seventy-five strains of C. difficile recently isolated from stool samples of patients with PMC or antibiotic-associated diarrhea were studied. The antimicrobial agents evaluated were provided as standard laboratory powder. Vancomycin was manufactured by United States Biochemical Corp., Cleveland, Ohio, and teicoplanin was manufactured by Lepetit Research Laboratories, Milan, Italy.
The MIC was determined by the agar dilution method (7) vancomycin and teicoplanin were dissolved in phosphatebuffered saline. The following samples were prepared: cholestyramine alone (12 mg/ml), vancomycin alone (2 mg/ml), teicoplanin alone (2 mg/ml), cholestyramine (12 mg/ml) plus vancomycin (2 mg/ml), and cholestyramine (12 mg/ml) plus teicoplanin (2 mg/ml). The samples were incubated in a water bath, with agitation at 37°C for 1 h, and then centrifuged at 8,000 x g for 15 min. The decanted supernatants, appropriately diluted, were assayed for antibacterial activity by an agar diffusion technique with Bacillus subtilis ATCC 6633 as the test organism; standard solutions of vancomycin and teicoplanin were tested in the same assay to determine the concentration of these drugs in the samples. All samples were tested in triplicate.
All strains tested were highly susceptible to both vancomycin and teicoplanin, with MICs distributed over a narrow range; however, MICs of teicoplanin were found to be fourfold lower than those of vancomycin. Vancomycin MICs for 50 and 90% of strains were 0.5 and 1 [Lg/ml, respectively, and the MIC range was 0.25 to 1 ,ug/ml. The teicoplanin MIC for both 50 and 90% of strains was 0.25 p.g/ml, and the MIC range was 0.12 to 0.5 [.g/ml. The results of the experiment to determine the binding of the two antibiotics by cholestyramine are summarized in Table 1 . The presence of cholestyramine produced a fall in the active vancomycin concentration of approximately 20%, that is, 80% binding. With teicoplanin, the fall in active concentration was more striking. This antibiotic appeared to be almost entirely bound by cholestyramine, and its activity was hardly detected by plate assay.
Vast clinical experience has proven vancomycin to be highly effective against C. difficile-induced PMC and diarrhea. However, its cost and the high incidence of relapses 
